List of insiders holdings for Spyre Therapeutics Inc.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
# | Insider Holder Name | Report Date Time |
Shares Owned Directly Indirectly |
Total Shares Owned |
Filing |
1 | Alspaugh Jonathan President and CFO |
2023-06-30 16:34:47 | 19,787,969 0 |
19,787,969 | Form 4 |
2 | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director |
2024-04-25 16:55:38 | 0 5,176,222 |
5,176,222 | Form 4 |
3 | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner |
2024-04-25 16:40:00 | 4,508,579 0 |
4,508,579 | Form 13D |
4 | Lilly Ventures Fund I LLC Shanafelt Armen Torres S. Edward 10% Owner |
2021-02-12 16:59:33 | 2,568,543 0 |
2,568,543 | Form 13G |
5 | Lawton Alison Frances Director |
2023-06-30 16:30:12 | 1,950,000 0 |
1,950,000 | Form 4 |
6 | Smith Hunter C Director |
2023-06-30 16:31:16 | 1,950,000 0 |
1,950,000 | Form 4 |
7 | Magovcevic-Liebisch Ivana Director |
2023-06-30 16:32:34 | 1,950,000 0 |
1,950,000 | Form 4 |
8 | Cox Russell J. Director |
2023-06-30 16:33:37 | 1,950,000 0 |
1,950,000 | Form 4 |
9 | Goldberg Jeff Marc President and CEO |
2022-12-01 20:47:37 | 1,884,838 0 |
1,884,838 | Form 4 |
10 | ORBIMED ADVISORS LLC OrbiMed Capital GP V LLC ISALY SAMUEL D 10% Owner |
2023-02-14 16:01:11 | 1,797,221 0 |
1,797,221 | Form 13G |
11 | LILLY ELI & CO Lilly Ventures Fund I LLC Shanafelt Armen 10% Owner |
2022-02-10 16:13:03 | 1,526,516 0 |
1,526,516 | Form 13G |
12 | Quinn Anthony G. President & CEO |
2022-03-18 06:46:58 | 550,540 266,295 |
816,835 | Form 4 |
13 | Novartis Bioventures Ltd NOVARTIS AG 10% Owner |
2020-01-30 16:12:04 | 617,769 0 |
617,769 | Form 13G |
14 | Neuman Linda L Chief Medical Officer |
2023-02-24 18:25:30 | 550,000 0 |
550,000 | Form 4 |
15 | Kastenmayer James Paul General Counsel |
2023-02-24 18:24:11 | 500,000 0 |
500,000 | Form 4 |
16 | Hanley Jr. Michael Conick Chief Business Officer |
2023-02-24 18:22:20 | 500,000 0 |
500,000 | Form 4 |
17 | Turtle Cameron Chief Executive Officer |
2025-01-17 16:35:13 | 370,000 0 |
370,000 | Form 4 |
18 | HENDERSON MICHAEL THOMAS Director |
2025-01-14 17:16:29 | 210,758 0 |
210,758 | Form 4 |
19 | Rojas-Caro Sandra Chief Medical Officer |
2016-05-19 16:37:04 | 200,000 0 |
200,000 | Form 4 |
20 | GEORGIOU GEORGE Director |
2018-08-15 16:40:25 | 192,528 0 |
192,528 | Form 4 |
21 | Lowe David George CEO and President |
2017-03-22 16:53:40 | 160,000 0 |
160,000 | Form 4 |
22 | Sloan Leslie Chief Operating Officer |
2022-08-25 19:36:17 | 130,000 0 |
130,000 | Form 4 |
23 | York Charles N II Chief Financial Officer and VP |
2020-02-19 17:15:29 | 126,000 0 |
126,000 | Form 4 |
24 | Burrows Scott L Chief Financial Officer |
2025-01-17 16:36:48 | 95,500 0 |
95,500 | Form 4 |
25 | Sloan Sheldon Chief Medical Officer |
2025-01-17 16:36:00 | 95,500 0 |
95,500 | Form 4 |
26 | King-Jones Heidy See Remarks |
2025-01-17 16:34:06 | 95,500 0 |
95,500 | Form 4 |
27 | Souza Marcio Director |
2022-08-25 19:37:05 | 90,000 0 |
90,000 | Form 4 |
28 | Schuchart Aaron Chief Business Officer |
2019-03-01 17:09:04 | 60,000 0 |
60,000 | Form 4 |
29 | Wooldridge James Chief Medical Officer |
2019-03-01 17:09:49 | 50,200 0 |
50,200 | Form 4 |
30 | Shanafelt Armen Director |
2022-06-09 21:22:33 | 43,000 0 |
43,000 | Form 4 |
31 | Mahatme Sandesh Director |
2022-06-09 21:18:44 | 43,000 0 |
43,000 | Form 4 |
32 | LAWLIS V BRYAN Director |
2022-06-09 21:15:38 | 43,000 0 |
43,000 | Form 4 |
33 | McKenna Mark C. Director |
2024-02-05 17:29:40 | 40,000 0 |
40,000 | Form 4 |
34 | Hebel Henry VP, Product Development |
2017-03-22 16:52:59 | 38,200 0 |
38,200 | Form 4 |
35 | Weber Steven VP, Controller&Princ Acctg Off |
2022-02-22 16:55:42 | 30,000 0 |
30,000 | Form 4 |
36 | Bruhn Suzanne Louise Director |
2020-06-10 16:21:57 | 28,100 0 |
28,100 | Form 4 |
37 | Albers Jeffrey W. Director |
2024-11-08 16:53:52 | 0 27,360 |
27,360 | Form 4 |
38 | Rao Madduri Ravin Chief Medical Officer |
2020-02-19 17:14:05 | 25,000 0 |
25,000 | Form 4 |
39 | TYLER JOSEPH E VP, Manufacturing |
2017-08-24 18:03:31 | 25,000 0 |
25,000 | Form 4 |
40 | Rowlinson Scott W VP, Research |
2017-08-24 18:02:15 | 25,000 0 |
25,000 | Form 4 |
41 | Fairmount Funds Management LLC Kiselak Tomas Harwin Peter Evan Director |
2024-05-16 16:10:28 | 0 22,646 |
22,646 | Form 4 |
42 | Milligan Sandra Director |
2024-05-16 16:10:27 | 21,980 0 |
21,980 | Form 4 |
43 | Stelzer Laurie Director |
2024-05-16 16:10:16 | 11,323 0 |
11,323 | Form 4 |
44 | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director |
2024-02-14 16:21:51 | 0 0 |
0 | Form 13G |
45 | Brownstein Sara Director |
2021-02-25 19:30:36 | 0 0 |
0 | Form 3 |